The e-commerce giant got an expensive bill for CEO Jack Ma critiquing regulators for stifling innovation.
New Delhi [India], May 7 (ANI): Department of posts and customs authorities have collaborated to start a helpline to facilitate speedy delivery of COVID-related emergency shipments, said the Ministry of Communications on Friday.
Canada lost more jobs than expected in April, with the declines driven by coronavirus restrictions in populous Ontario, Quebec and British Columbia, while the unemployment rate rose, Statistics Canada data showed on Friday. "Full-time jobs took a heavier hit during April than they did amid the second wave restrictions," said Doug Porter, chief economist at BMO Capital Markets.
Here's a list of the best self-care gift ideas for new graduates, as chosen by Engadget editors.
Hurray, I can meet people! Now, when can I get some alone time?. Could it be that I, a committed extrovert who talks to strangers, had become an introvert during the pandemic?
Jamali Maddix: ‘I don’t dream. It’s overrated’ . The writer, actor, standup and documentary-maker on the things that make him laugh the most
Drink brands that won’t cost the earth. Many brands claim to be ethical these days, but how to tell which ones are really up to scratch? Here are some tipples that are worthy inside and out
I thought I’d quit my trainer addiction – then along came some Yeezy slides. I got an email saying I could enter a raffle where the prize is spending a load of money on something I had not intention of buying previously
Psychedelic spring colours and some spectacular surf – the week in art. Jim Lambie’s pulsing palette returns, Carol Rhodes shakes up the landscape and the late great Takis unleashes some cosmic vibrations – all in your weekly dispatch
If you ask Jeremy Lang, he’ll tell you flax has some impressive flex, though you might be surprised where that comes in handy — like a case in the palm of your hand, wrapped around your cellphone. The kicker: They’re biodegradable. Those same flax fibres help your discarded case return to the earth in an appropriate, ecological timeframe (maximum one year in a home compost) after you switch out for a new case. He launched the first model just under 10 years ago out of Saskatoon, when Apple released its iPhone 4s. “The weird thing was the (plastic) case you use to protect it would last for hundreds of thousands of years; most people only kept their phones for two years,” Lang said in an interview. His company, Pela, has grown considerably since he started it at Innovation Place at the University of Saskatchewan campus. Pela moved its headquarters to Kelowna in 2018, while keeping operations in Saskatoon and expanding them to the U.S., Germany, Hong Kong and China. It now sells compostable cases for 16 iPhone models and 29 Android-based models. Ditto for straps that need a smart watch. There’s a line of earth-friendly sunglasses, too. Despite Pela’s global growth, its roots are in Saskatchewan’s agriculture scene, says Lang, who grew up in Regina and Yorkton and earned a Bachelor of Science in Agriculture from the U of S. Driving northeast on Highway 10 to Yorkton as a kid, he recalled, “through the valley at harvest time, the sky was glowing orange. It was getting to be night time, and coming out of the valley I saw these fields on fire.” His dad told him, "the farmers are burning their flax straw, because they grow it for the oil seed, but the fibre in the straw is so strong it gets caught up in their equipment, so they burn it.” He figured if it’s that strong, it ought to be good for something. Hence the phone cases. “It has shock-absorption qualities to it … in Europe they grow flax for the fibre and the straw, not the oil seed,” he said, referencing its use in bike frames and tennis rackets. That, plus flax’s biodegradable qualities make for a useful phone case ingredient, he said. Lang also believes it’s important to create a market for farmers where they can sell their baled flax stubble, instead of torching it: Bale processors buy them and break them down into tiny pieces, which Pela buys and puts into its heat-moulded cases, along with coloured biopolymers. He likened the end product to "a cork-like material" with some eye-catching flax flecks. Looking ahead, Pela is in the crowdfunding phase of a counter-top, food-scraps composter called Lomi. Lang says it’s to play a big role in the company reaching its 2028 goal: One billion pounds of waste diverted from landfills, every year, a big chunk of which is all that plastic from those seemingly brick-like cases. “It's the whole concept of using things as many times as we can and then they have a graceful end of life … so it goes back to the earth and mimics nature,” he said. firstname.lastname@example.org Evan Radford, Local Journalism Initiative Reporter, Regina Leader-Post, The Leader-Post
The U.S. economy added disappointing 266K jobs in April even as states relaxed business restrictions and vaccinations increased. Unemployment rose to 6.1%.
Shop the shorts version of Jennifer Garner’s favorite leggings.
-- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma -- Medicenna’s proposed patient population shows a tumor control rate of 81% (26/32) based on modified RANO criteria TORONTO and HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the peer-reviewed publication of clinical data from the Company’s Phase 2b recurrent glioblastoma (rGBM) trial in Clinical Cancer Research. The paper, entitled “Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-enhanced Delivery of IL4R-targeted Immunotoxin MDNA55 in Recurrent Glioblastoma,” was published in collaboration with researchers at several prestigious institutions including University of California Los Angeles and Duke University. Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna, commented, “This Phase 2b trial has generated compelling data, and we are very pleased to have them published in such a prestigious peer-reviewed journal. In particular, we are highly encouraged by results showing that early determination of progression free survival (PFS) using modified RANO (mRANO) may be a strong surrogate for overall survival in rGBM. We believe this finding and the positive mRANO PFS and overall survival (OS) data from our proposed patient population bode well for the outcome of the planned Phase 3 trial, which utilizes an innovative open label hybrid design with OS as the primary endpoint. Medicenna is pursuing a partnership strategy to continue the Phase 3 development.” The Phase 2b trial evaluated MDNA55, an interleukin-4 (IL-4)-guided toxin, as a treatment for rGBM, the most common and uniformly fatal form of brain cancer. Results presented in the peer-reviewed paper show that the median OS of radiographically evaluable patients in the trial irrespective of dose or IL4R expression was 11.8 months, which is longer than what would be expected from the approved drugs carmustine (OS of 5.1 – 7.5 months)1,2, lomustine (OS of 7.1 – 9.8 months)3-5, or temozolomide (OS of 5.4 – 9.9 months)3,6,7. Notably, the data also show a potential link between patients experiencing radiographic progression and those exhibiting insufficient MDNA55 penetration into the tumor, suggesting that at least a portion of patients who did not respond well to MDNA55 may have benefited from higher drug concentrations. Additional analyses from the publication show that both locally and centrally determined PFS using mRANO criteria strongly correlated with OS, suggesting that the mRANO criteria may be superior to the standard RANO and iRANO at predicting OS, particularly for immunotherapies. These analyses supplement previously presented findings observed in Medicenna’s proposed patient population showing an 81% tumor control rate (26/32) based on mRANO and a median OS of 15.7 months, which represents a >100% improvement compared to an external control arm (median OS of 7.2 months). The proposed patient population included all MDNA55-treated trial participants with high IL4R expression and participants with low IL4R expression that received a high dose of MDNA55 treatment. Medicenna is currently pursuing a partnership strategy to facilitate MDNA55’s further development through the planned Phase 3 clinical trial. Following an End of Phase 2 meeting with the United States Food and Drug Administration (FDA), the agency agreed that Medicenna could conduct an open label hybrid Phase 3 trial that allows use of a substantial number of subjects (two-thirds) from a matched external control arm to support regulatory approval of MDNA55 for rGBM. The FDA also expressed their willingness to consider an interim analysis of the trial if certain criteria are met. Unlike conventional randomized control trials, the hybrid trial design will reduce the overall number of subjects needed in the study to achieve the primary endpoint as well as reduce the cost and timelines associated with completing the trial. References Brandes AA et al. Neurology 2004; 63: 1281–4.Reithmeier T et al. BMC Cancer 2010; 10: 30.Weller M et al. Neuro Oncol 2013; 15: 4–27.Wick W et al. J Clin Oncol 2010;28: 1168–74.Batchelor TT et al. J Clin Oncol 2013; 31: 3212–8.Balmaceda C et al. Cancer 2008;112: 1139–46.Wick A et al. J Clin Oncol 2007;25:3357–61. About Medicenna Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL-2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna’s early-stage program on Bifunctional SuperKine ImmunoTherapies (BiSKITs™) is designed to further enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively. Forward-Looking StatementThis news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts including statements related to a potential partnership for MDNA55. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "believes" and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law. CONTACT: Further Information For further information about the Company please contact: Elizabeth Williams, Chief Financial Officer, 416-648-5555, email@example.com Investor Contact For more investor information, please contact: Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, firstname.lastname@example.org
SpareBox Storage, a national self storage platform focused on consolidating the highly fragmented self storage market across the United States, announced today that is has acquired 13 stabilized properties in Myrtle Beach, South Carolina and Amarillo, Texas from multiple sellers. Combined, these properties are comprised of approximately 330,000 net rentable square feet and 2,500 units with over 88% occupancy. The South Carolina portfolio acquisition opens a promising new market for SpareBox in one of the fastest growing markets in the nation, while enhancing the geographic diversification of the portfolio. The Amarillo acquisition is a perfect complement to the portfolio of Amarillo properties that SpareBox has previously acquired, and it delivers incremental operating efficiencies within the Amarillo market.
In recognition of World Fair Trade Day on May 8th, Nature's Path, North America's largest certified organic breakfast and snack food company is excited to announce it is deepening its Fairtrade commitments through the Fairtrade Sourced Ingredient program (FSI).
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the BofA Securities 2021 Health Care Conference at 11:45 a.m. ET on May 12, 2021.
National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, announced today that Chief Executive Officer, Reade Fahs, has become a signatory to the CEO Action for Diversity and Inclusion™ (CEO Action) pledge. National Vision is the first optical retailer represented in the growing coalition of nearly 2,000 business leaders across 85 industries committed to advancing diversity and inclusion goals in the workplace.
Hope Air today honoured CAA Club Group (CCG) with the Spirit of Hope Award 2020 for Outstanding Leadership and Philanthropy. This award recognizes the exemplary efforts of an organization that offers extraordinary support for Hope Air's mission to provide free flights and accommodations to patients in financial need.
A “huge” star? On a Saturday night? “It will be a party for sure.”
New York, New York--(Newsfile Corp. - May 7, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased XL Fleet Corp. (NYSE: XL) ("Xl Fleet") between October 2, 2020 and March 2, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/xl-fleet-corp-loss-submission-form?prid=15593&wire=5Allegations against XL include that the Company made materially false and/or ...
Tarsadia Capital, LLC together with its affiliates, associates and funds it manages ("Tarsadia"), today sent a letter and proxy statement to shareholders of Extended Stay America, Inc. (NYSE: STAY) ("ESA" or the "Company") and ESH Hospitality, Inc. ("ESH" and together with the Company, the "Paired Entities") encouraging shareholders to reject the acquisition of STAY by Blackstone Real Estate Partners and Starwood Capital Group for $19.50 per paired share (the "Sale"). The Sale is subject to a vote of shareholders at the upcoming Special Meeting of Shareholders ("the Special Meeting") scheduled to be held on June 8, 2021.